International Journal of Medical Sciences

Impact factor
2.399

13 December 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2012; 9(10):901-908. doi:10.7150/ijms.4655

Research Paper

Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia

Miwako Narita1✉, Anri Saito1, Aya Kojima1, Minami Iwabuchi1, Naoya Satoh1, Takayoshi Uchiyama1, Akie Yamahira1, Tatsuo Furukawa2, Hirohito Sone3, Masuhiro Takahashi1

1. Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, 1-746 Asahimachi-dori, Chuo-ku, Niigata, 951-8518 Japan;
2. Division of Bone Marrow Transplantation, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-dori, Chuo-ku, Niigata, 951-8520, Japan;
3. Division of Hematology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Niigata University, Niigata, 951-8510, Japan.

Abstract

Quantification of tumor-associated mRNA extracted from blood cells/tissues containing tumor cells is used for evaluation of treatment efficacy or residual tumor cell burden in tumors including leukemia. However, this method using tumor cell-containing blood/tissue is difficult to evaluate the whole tumor cell burden in the body. In order to establish an efficient method to evaluate the whole tumor cell burden in the body, we tried to quantify tumor-associated mRNA existing in plasma/serum instead of leukemia cell-containing blood cells in patients with chronic myelogenous leukemia (CML) and compared the levels of BCR-ABL mRNA between plasma/serum and peripheral blood cells. mRNA of BCR-ABL, WT1 or GAPDH (control molecule) was detected by real-time RT-PCR using RNA extracted from plasma/serum of almost all the patients with CML. Copy numbers of BCR-ABL mRNA were significantly correlated between plasma/serum and peripheral blood cells. However, levels of BCR-ABL mRNA extracted from serum were low compared with those extracted with peripheral blood cells. The present findings suggest that although real-time RT-PCR of mRNA existing in plasma/serum could be used for evaluating the whole tumor cell burden in the body, it's required to establish an efficient method to quantify plasma/serum mRNA by nature without degrading during the procedure.

Keywords: serum, plasma, mRNA, CML, BCR-ABL, WT1, real-time RT-PCR.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Narita M, Saito A, Kojima A, Iwabuchi M, Satoh N, Uchiyama T, Yamahira A, Furukawa T, Sone H, Takahashi M. Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia. Int J Med Sci 2012; 9(10):901-908. doi:10.7150/ijms.4655. Available from http://www.medsci.org/v09p0901.htm